Can Fite Biopharma Ltd ADR is a biotechnology business based in the US. Can Fite Biopharma Ltd ADR shares (CANF) are listed on the NYSE MKT and all prices are listed in US Dollars. Can Fite Biopharma Ltd ADR employs 8 staff and has a trailing 12-month revenue of around $743,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.52 |
|---|---|
| 52-week range | $1.81 - $4.56 |
| 50-day moving average | $2.72 |
| 200-day moving average | $2.27 |
| Wall St. target price | $15.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.00 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.52 from 2024-07-25
| 1 week (2024-07-19) | -21.78% |
|---|---|
| 1 month (2024-06-27) | 37.50% |
| 3 months (2024-04-26) | 77.78% |
| 6 months (2024-01-26) | 79.59% |
| 1 year (2023-07-27) | 19.32% |
|---|---|
| 2 years (2022-07-27) | 319.05% |
| 3 years (2021-07-27) | 72.55% |
| 5 years (2019-07-26) | 19.32% |
| Revenue TTM | $743,000 |
|---|---|
| Gross profit TTM | $810,000 |
| Return on assets TTM | -53.15% |
| Return on equity TTM | -142.49% |
| Profit margin | 0% |
| Book value | $0.01 |
| Market Capitalization | $22.5 million |
TTM: trailing 12 months
We're not expecting Can Fite Biopharma Ltd ADR to pay a dividend over the next 12 months.
Can Fite Biopharma Ltd ADR's shares were split on a 1:10 basis on 8 January 2023. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Can Fite Biopharma Ltd ADR shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Can Fite Biopharma Ltd ADR shares which in turn could have impacted Can Fite Biopharma Ltd ADR's share price.
Over the last 12 months, Can Fite Biopharma Ltd ADR's shares have ranged in value from as little as $1.81 up to $4.5599. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Can Fite Biopharma Ltd ADR's is 0.687. This would suggest that Can Fite Biopharma Ltd ADR's shares are less volatile than average (for this exchange).
Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd.
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.